Bladder Cancer
PARP Inhibitor ABT-888 with Carboplatin & Gemcitabline (M10-758) (UW09039)
A Phase 1 Study of ABT-888 (Veliparib) in Combination With Carboplatin (Paraplatin) and Gemcitabline (Gemzar) in Subjects With Advanced Solid Tumors
Investigator: Heidi J. Gray, MD; Conditions: Advanced Solid Tumors; Status: Not Recruiting; Study ID: NCT01063816
A Randomized, Double-blind Phase 2 Study Comparing Gemcitabine and Cisplatin in Combination With OGX-427 or Placebo in Patients With Advanced Transitional Cell Carcinoma
Investigator: Evan Ya-Wen Yu, MD; Conditions: Urologic Neoplasms, Metastatic Bladder Cancer, Urinary Tract Neoplasms; Status: Recruiting; Study ID: NCT01454089
Join Us On